# Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)

Study · id `cardio:ct-nct05321875` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05321875](<https://clinicaltrials.gov/study/NCT05321875>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05321875

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 320 participants.

## Technical summary

Registry record NCT05321875. Randomized; quadruple masking; primary purpose prevention. Start 2022-06-02 (actual); primary completion 2026-06-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 320 participants (planned count; ClinicalTrials.gov record NCT05321875, source copy `cardio:ctgov-nct05321875-2024-11-07`, retrieved 2026-10-31)
- Started: 2022-06-02 (actual) (ClinicalTrials.gov record NCT05321875, source copy `cardio:ctgov-nct05321875-2024-11-07`, retrieved 2026-10-31)
- Primary completion: 2026-06-02 (anticipated) (ClinicalTrials.gov record NCT05321875, source copy `cardio:ctgov-nct05321875-2024-11-07`, retrieved 2026-10-31)
- Completion: 2026-06-02 (anticipated) (ClinicalTrials.gov record NCT05321875, source copy `cardio:ctgov-nct05321875-2024-11-07`, retrieved 2026-10-31)
- Countries: Spain (ClinicalTrials.gov record NCT05321875, source copy `cardio:ctgov-nct05321875-2024-11-07`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05321875-2024-11-07`, retrieved 2026-10-31)

## The registry's words

- Brief title: Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)
- Acronym: EARLY-GENE
- Condition: Cardiomyopathy, Dilated
- Intervention (Drug): Candesartan
- Lead sponsor: Cristina Avendaño Solá
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Dilated cardiomyopathy (`cardio:dilated-cardiomyopathy`)
- Registry intervention name matches this record: Candesartan (`cardio:candesartan`)
- Registry intervention is a member of this class by a sourced record link: Angiotensin receptor blockers (ARBs) (`cardio:angiotensin-receptor-blockers-arbs`)

## Provenance

Content hash: 43f26f50396fecedfbdf1cf8539303e67545248556c86cf79e58b7c2de45a8a6
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
